Navigation Links
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
Date:10/29/2010

r 706-679-1941 (international) and reference the access code 22130601. A live audio webcast of the conference call will be available by visiting AVANIR's website at www.avanir.com.  To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary software. An archive of the conference call will be available on the Company's website for 30 days.

About NUEDEXTA

NUEDEXTA™ is the first and only FDA-approved treatment for pseudobulbar affect (PBA).  NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations.  NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.  

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA).  PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying.  PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state.  Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).  NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias.  The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a signi
'/>"/>

SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... BerGenBio AS, a biopharmaceutical company ... cancers, today announces that it has raised NOK90 million ... and existing investors. BerGenBio will use the ... its pipeline of innovative cancer therapeutics, in particular an ... BGB324, a first-in-class selective Axl kinase inhibitor, which is ...
(Date:12/15/2014)... , Dec. 15, 2014  Inovio Pharmaceuticals, Inc. ... has been added to the NASDAQ Biotechnology Index ... will become effective upon market open on December ... is designed to track the performance of a ... either biotechnology or pharmaceutical according to the Industry ...
(Date:12/15/2014)... Dec. 15, 2014  Colorado and Washington State ... adult use of cannabis. Oregon , ... ended prohibition during the November 2014 elections. ... http://photos.prnewswire.com/prnh/20141212/164153LOGO The benefits of legalizing ... obvious benefits like the increased tax revenue for state and ...
Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2
... Esperion Therapeutics, a privately held biotechnology company ... cardiovascular and metabolic diseases, today announced that it ... ETC-1002, the company,s lead product candidate. ETC-1002 is ... preclinical and clinical activity as a metabolic regulator ...
... 6, 2011 ChemoCentryx, Inc., today announced that Thomas ... present at J.P. Morgan,s 29 th Annual Healthcare ... Pacific at the Westin St. Francis Hotel in San ... ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused ...
Cached Medicine Technology:Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002 2ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference 2
(Date:12/15/2014)... SIMpalm, a leading mobile app development ... for its client, which allows users to keep track ... in finding the right wine. At the center ... sensory, chemistry and wine information. All this information is ... Those wines that are close counterparts to one another ...
(Date:12/15/2014)... Boston, MA (PRWEB) December 15, 2014 ... health management solutions, announced today that it has ... for Quality Assurance (NCQA) for its Disease Management ... obstructive pulmonary disease (COPD), coronary heart disease and ... accreditation from NCQA for Health Dialog’s Disease Management ...
(Date:12/15/2014)... 14, 2014 (HealthDay News) -- Expert pilots process visual ... why they make better decisions during landings, a new ... difficult techniques for pilots to master, and 36 percent ... crashes occur during final approach and landing. Researchers ... 12 moderately experienced pilots while they were at the ...
(Date:12/15/2014)... CT (PRWEB) December 15, 2014 Kathy ... the prestigious Women World Awards in the category of ... a gold award for her weekly career blog ... practical advice to help professionals elevate their talent and ... Her blog, named after her book Networking Ahead for ...
(Date:12/15/2014)... In support of high-quality independent ... restrictive state laws that may have unintended consequences ... area of public health policy. , The position ... of Independent Review, contends that state legislation that ... review determinations can result in subpar outcomes for ...
Breaking Medicine News(10 mins):Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... University of Pennsylvania School of Medicine discovered that proteins ... exposed to the tau protein, which plays an important ... proteins transport cellular cargo towards opposite ends of tracks ... acts like a speed bump to regulate protein traffic, ...
... CHICAGO, Jan. 17 Bankers Life and Casualty Company ... Health and Human,Services in implementing a study with senior ... over age 65 fall each year, and falls,are a ... cause of nonfatal,injuries," said Scott Perry, president of Bankers, ...
... answer may depend on outcomes of ongoing clinical trials, expert ... reports that statins might slow or prevent Alzheimer,s disease, a ... While some animal studies have suggested this possibility, whether the ... said. , "We didn,t find a relation between statin ...
... researchers say , , THURSDAY, Jan. 17 (HealthDay News) -- By ... say they,re gaining new insight into how some children are ... report in a new study that both twins -- one ... that mutated and became precancerous. In one of the twins, ...
... ... young children., BERKELEY SPRINGS, W.Va., Jan. 17 The US ... is too risky,for babies and toddlers on Thursday according to recent ... parents of the serious and,potentially life threatening side effects of cold ...
... for Life-Threatening, Genetic,Disease, WASHINGTON, Jan. 17 All ... beginning today. Montana is the,37th state in the country, ... states that support routine CF screening at birth., ... states dedicated,to supporting newborn screening for cystic fibrosis," said ...
Cached Medicine News:Health News:Alzheimer's molecule is a smart speed bump on the nerve-cell transport highway 2Health News:Bankers Life and Casualty Company Joins LifePlans, Inc. and the Department of Health and Human Services to Launch Fall Prevention Program Study For America's Seniors 2Health News:Latest Study Says Statins Don't Slow Alzheimer's 2Health News:Study Gets Closer to Origins of Leukemia 2Health News:FDA to Declare Cold Medicines Too Risky, Homeopathy Offers a Safe Alternative 2Health News:Montana Passes Newborn Screening Law for Cystic Fibrosis 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: